Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:33:42.887Z.
Calculation as of: 2026-10-06T16:33:42.887Z.
Quote observation: 2026-10-06T16:29:45.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 11bda5a52c13142378ae00f1a27abc282066b453892c652a9842cb594787c7ab
PE RATIO
N/A
Market Cap
$110.27M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.61M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MaxCyte, Inc. (MXCT) | $112.77M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.61M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $115.69M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.65M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $117.03M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $110.27M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.61M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.49M | N/A | 3.95 | 3.95 | 3.95 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.05
Forward EPS (Est.)
$-0.28
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
